Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | TP53 P72R |
Therapy | Cyclophosphamide + Epirubicin + Fluorouracil |
Indication/Tumor Type | breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 P72R | breast cancer | predicted - sensitive | Cyclophosphamide + Epirubicin + Fluorouracil | Phase I | Actionable | In a Phase I trial, breast cancer patients harboring TP53 P72R were reported to have a better response to anthracycline-based neoadjuvant therapies, including Ellence (epirubicin) in combination with Cytoxan (cyclophosphamide) and Adrucil (fluorouracil) (PMID: 16243804). | 16243804 |
PubMed Id | Reference Title | Details |
---|---|---|
(16243804) | p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. | Full reference... |